ABOS Projected Dividend Yield
Acumen Pharmaceuticals Inc ( NASDAQ : ABOS )Acumen Pharmaceuticals discovers and develops targeted therapies for the treatment of Alzheimer's disease. Co.'s primary drug candidate, ACU193, is a humanized monoclonal antibody which selectively targets amyloid-beta oligomers. Co. holds exclusive rights to the program. 20 YEAR PERFORMANCE RESULTS |
ABOS Dividend History Detail ABOS Dividend News ABOS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |